Ladenburg Thalmann Financial Services’s Arbutus Biopharma ABUS Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$4.93M	Hold	1,774,915	–	–	0.03%	488
2019 Q3	$2.71M	Hold	1,774,915	–	–	0.02%	695
2019 Q2	$3.69M	Buy	1,774,915 +9,500	+0.5%	+$24.3K	0.03%	553
2019 Q1	$6.32M	Hold	1,765,415	–	–	0.05%	373
2018 Q4	$6.76M	Hold	1,765,415	–	–	0.06%	287
2018 Q3	$17.1M	Buy	1,765,415 +100	+0%	+$993	0.14%	149
2018 Q2	$8.83M	Hold	1,765,315	–	–	0.08%	230
2018 Q1	$8.83M	Hold	1,765,315	–	–	0.08%	230
2017 Q4	$8.91M	Sell	1,765,315 -3,576	-0.2%	-$21K	0.09%	222
2017 Q3	$13.3M	Sell	1,768,891 -3,526,054	-67%	-$15.1M	0.14%	147
2017 Q2	$19.1M	Hold	5,294,945	–	–	0.22%	105
2017 Q1	$17.2M	Hold	5,294,945	–	–	0.22%	104
2016 Q4	$13M	Buy	5,294,945 +5,294,445	+1,058,889%	+$15.4M	0.18%	123
2016 Q3	$2K	Buy	+500	New	+$1.95K	﹤0.01%	4437
2015 Q3	–	Sell	-300	Closed	-$4K	–	4589
2015 Q2	$4K	Hold	300	–	–	﹤0.01%	4108
2015 Q1	$5K	Buy	+300	New	+$6.14K	﹤0.01%	3948

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Ladenburg Thalmann Financial Services's ABUS Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services held its Arbutus Biopharma (ABUS) position steady in Q4 2019 at 1,774,915 shares worth $4.93M. The position accounts for 0.03% of the portfolio, ranked #488.

Ladenburg Thalmann Financial Services first reported a position in ABUS in Q1 2015 and has held it in 16 quarters since. The position peaked at $19.1M in Q2 2017. 59 funds tracked by Wall St. Rank hold ABUS as of Q4 2019.

Ladenburg Thalmann Financial Services held 1,774,915 shares of Arbutus Biopharma worth $4.93M as of Q4 2019.
Ladenburg Thalmann Financial Services left its Arbutus Biopharma share count unchanged in Q4 2019.
Arbutus Biopharma made up 0.03% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #488 holding.
Ladenburg Thalmann Financial Services first reported a position in Arbutus Biopharma in Q1 2015 and has held it in 16 quarters since.
Ladenburg Thalmann Financial Services's Arbutus Biopharma position peaked at $19.1M in Q2 2017.
59 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.